Cardiff Other Operating Expenses vs Ebitda Analysis
CRDF Stock | USD 3.78 1.34 54.92% |
Cardiff Oncology financial indicator trend analysis is way more than just evaluating Cardiff Oncology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiff Oncology is a good investment. Please check the relationship between Cardiff Oncology Other Operating Expenses and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
Other Operating Expenses vs Ebitda
Other Operating Expenses vs Ebitda Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiff Oncology Other Operating Expenses account and Ebitda. At this time, the significance of the direction appears to have pay attention.
The correlation between Cardiff Oncology's Other Operating Expenses and Ebitda is -0.99. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Ebitda in the same time period over historical financial statements of Cardiff Oncology, assuming nothing else is changed. The correlation between historical values of Cardiff Oncology's Other Operating Expenses and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Cardiff Oncology are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Other Operating Expenses i.e., Cardiff Oncology's Other Operating Expenses and Ebitda go up and down completely randomly.
Correlation Coefficient | -0.99 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cardiff Oncology. It is also known as Cardiff Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Ebitda
Most indicators from Cardiff Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiff Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.The current Selling General Administrative is estimated to decrease to about 7.5 M. The current Issuance Of Capital Stock is estimated to decrease to about 16.3 M
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 264K | 1.6M | 3.8M | 4.0M | Cost Of Revenue | 500K | 200K | 32.9M | 34.5M |
Cardiff Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Cardiff Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardiff Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 13.1M | 134.7M | 149.5M | 116.2M | 81.6M | 45.3M | |
Total Stockholder Equity | 7.3M | 128.2M | 140.4M | 106.3M | 69.7M | 36.9M | |
Net Debt | (8.5M) | (130.1M) | (8.8M) | (13.6M) | (19.5M) | (20.5M) | |
Cash | 10.2M | 131.0M | 11.9M | 16.3M | 21.7M | 24.3M | |
Cash And Short Term Investments | 10.2M | 131.0M | 140.8M | 105.3M | 74.8M | 41.8M | |
Common Stock Shares Outstanding | 6.0M | 20.9M | 39.0M | 43.6M | 44.7M | 46.9M | |
Liabilities And Stockholders Equity | 13.1M | 134.7M | 149.5M | 116.2M | 81.6M | 45.3M | |
Other Stockholder Equity | 217.2M | 359.6M | 400.4M | 404.8M | 409.3M | 429.8M | |
Total Current Assets | 11.4M | 133.4M | 146.1M | 111.3M | 77.4M | 43.3M | |
Common Stock | 7.7K | 8.3K | 3.7K | 4K | 3.6K | 3.4K | |
Other Current Liab | 3.3M | 3.9M | 4.0M | 4.5M | 7.1M | 7.4M | |
Total Current Liabilities | 4.8M | 6.1M | 6.6M | 7.8M | 10.4M | 5.4M | |
Property Plant And Equipment Net | 1.6M | 966.7K | 3.2M | 3.5M | 2.9M | 1.8M | |
Retained Earnings | (208.9M) | (231.5M) | (259.8M) | (298.1M) | (339.5M) | (322.6M) | |
Accounts Payable | 656K | 1.4M | 1.4M | 2.0M | 2.0M | 1.3M | |
Non Current Assets Total | 1.7M | 1.4M | 3.4M | 4.9M | 4.2M | 2.3M | |
Non Currrent Assets Other | 103K | (813.7K) | (1.8M) | 1.4M | 1.3M | 1.3M | |
Net Receivables | 204K | 320.5K | 535K | 771K | 288K | 225.2K | |
Non Current Liabilities Total | 994K | 450.5K | 2.6M | 2.0M | 1.5M | 1.4M | |
Other Current Assets | 955K | 2.1M | 4.8M | 5.2M | 2.3M | 1.5M | |
Total Liab | 5.8M | 6.6M | 9.1M | 9.8M | 11.9M | 11.2M | |
Property Plant And Equipment Gross | 1.6M | 966.7K | 3.2M | 3.5M | 6.7M | 7.0M | |
Accumulated Other Comprehensive Income | (971.7K) | (2.2M) | (142K) | (395K) | (67K) | (70.4K) | |
Common Stock Total Equity | 7.7K | 8.3K | 3.7K | 4K | 4.6K | 4.7K | |
Net Tangible Assets | 7.3M | 128.2M | 140.4M | 106.3M | 122.3M | 128.4M | |
Retained Earnings Total Equity | (208.9M) | (231.5M) | (259.8M) | (298.1M) | (268.3M) | (281.7M) | |
Capital Surpluse | 217.2M | 361.8M | 400.5M | 404.8M | 465.6M | 249.6M | |
Deferred Long Term Liab | 1.8M | 1.1M | 4.1K | 285.0K | 256.5K | 243.7K | |
Property Plant Equipment | 877.8K | 623.7K | 382K | 1.3M | 1.1M | 1.2M | |
Other Assets | 157.6K | 404.2K | 239K | 1.4M | 1.0 | 0.95 | |
Other Liab | 1.8M | 1.2M | 132.5K | 441.2K | 397.1K | 377.3K | |
Net Invested Capital | 7.3M | 128.2M | 140.4M | 106.3M | 69.7M | 73.8M | |
Net Working Capital | 6.6M | 127.2M | 139.6M | 103.5M | 67.0M | 72.2M |
Currently Active Assets on Macroaxis
When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.015 | Quarterly Revenue Growth 0.17 | Return On Assets (0.38) | Return On Equity (0.68) |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.